

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**VOLUNTARY ANNOUNCEMENT**  
**PROPOSED INCREASE IN SHAREHOLDING BY CONTROLLING**  
**SHAREHOLDERS AND EXECUTIVE DIRECTORS**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (“**Director(s)**”) of the Company was informed by Dr. Xuefeng YU (the chairman of the Board, the chief executive officer, general manager and a controlling shareholder of the Company, “**Dr. Yu**”), Dr. Shou Bai CHAO (an executive Director, the chief operating officer and deputy general manager of the Company, “**Dr. Chao**”), Dr. Tao ZHU (the chief scientific officer, deputy general manager and a controlling shareholder of the Company, “**Dr. Zhu**”) and Ms. Jing WANG (an executive Director, the chief commercial officer and deputy general manager of the Company, “**Ms. Wang**”) of their intention to purchase the H shares of the Company (the “**H Shares**”) from the open market (“**Shareholding Increase**”) within six months from the date of this announcement, subject to compliance with the applicable laws and regulations. According to Dr. Yu, Dr. Chao, Dr. Zhu and Ms. Wang (collectively, the “**Proposed Shareholding Increase Group**”), it is expected that the aggregate amount of consideration for the Shareholding Increase would not exceed HK\$10 million. In addition, the Proposed Shareholding Increase Group indicated that the H Shares proposed to be purchased would be held for medium-to long-term investment purposes, and they had no present intention to sell such H Shares during the six months after the Shareholding Increase. The funds required for the Shareholding Increase will be self-owned or self-raised funds.

The Board considers that the proposed Shareholding Increase indicates the Proposed Shareholding Increase Group’s full confidence in the prospect and potential of growth of the Company and the recognition of the Company’s long-term investment value.

As at the date of this announcement, the total shareholding interest in the Company of each member of the Proposed Shareholding Increase Group is set forth below.

<b>Name</b>	<b>Approximate % of total shareholding interest in the Company</b>
Dr. Yu	31.19%
Dr. Chao	6.60%
Dr. Zhu	31.19%
Ms. Wang	N/A

For further details, please refer to pages 67 to 69 of the Company's 2023 annual report.

Each member of the Proposed Shareholding Increase Group will ensure that he/she and/or persons acting in concert with him/her (having the meaning ascribed to it under the Code on Takeovers and Mergers) will not trigger a mandatory offer obligation under Rule 26.1 of the Code on Takeovers and Mergers as a result of the Shareholding Increase.

Based on the information available to the Company and to the knowledge and belief of the Directors, the Company will continue to maintain a sufficient public float of the shares in issue, if the Shareholding Increase is implemented.

**Shareholders and potential investors should note that the Proposed Shareholding Increase Group has the sole and absolute discretion to decide whether or not to proceed with the Shareholding Increase, and there is no assurance that the Shareholding Increase will take place or as to when it may take place. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, June 21, 2024

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive directors, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive directors.*